Lusine Harutyunyan, Hematologist, R1 Researcher at Yeolyan Hematology and Oncology Center, shared on LinkedIn:
”Another reviewer experience: case report published in Frontiers in Immunology
An intriguing BPDCN case report demonstrating a novel triple-integrated consolidation strategy, ASCT followed by autologous CD123 CAR T-cell therapy and c maintenance, achieving durable MRD–negative remission in a patient without an allo-HSCT donor. A promising proof of concept for expanding treatment options in this rare, aggressive malignancy.”
Title: Anti-CD123 CAR-T therapy combined with autologous SCT and venetoclax maintenance in refractory BPDCN ineligible for allogeneic transplantation: a case report and review of the literature
Authors: Fan Yang, Danyang Li, Yang Lei, Rui Liu, Zhonghua Fu, Lixia Ma, Biping Deng, Xiaoyan Ke, Kai Hu.
You can also read: ‘Peripheral T-Cell Lymphomas (PTCL): Another Evolving Lymphoma Story‘
